The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
about
Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current EvidenceOptofluidic device for the quantification of circulating tumor cells in breast cancer.Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy.Phenotype of circulating tumor cell: face-off between epithelial and mesenchymal masks.Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.Circulating tumor cells in breast cancer: applications in personalized medicine.Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy.Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry.Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.Microfilter-Based Capture and Release of Viable Circulating Tumor Cells.Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.Capture and Release of Viable Circulating Tumor Cells from Blood.[Circulating tumor cells: a real time dive into malignant plasticity].Improving the CellSearch® system.
P2860
Q28075850-FB1617B1-6B9B-473F-838A-0C114C48F314Q33808137-D0D934E0-74CD-4ED2-B3D3-B23E7858B050Q37352090-58E403F6-5A74-4433-A00D-A6BD3861E207Q38547813-B3C293FB-DBA9-4CE5-8506-53BFE36859C1Q38693785-F5A020E3-3C04-4BDB-B702-586E64A92061Q38862668-068ED91E-57AC-42DD-9796-371A0A5A9C20Q38985771-8DB050F9-2248-440A-8669-90C79B974752Q41233528-74A87490-94C1-473F-9450-C8D3B880397AQ41612814-40611D65-96AC-45E6-A89F-2DC17B5E1CE0Q41763224-CA4B664B-D0E1-4993-9F41-FB0F44AA38E4Q47781284-9BF6E23F-856A-44F2-9DDD-A2DFA7238FC3Q48230033-672DB5CC-C082-4912-8D35-B3BA3A8BA30FQ48325627-D54F500C-0ED8-4C26-BD14-277D3C061D68Q48934017-91EA2AD4-7724-4FBC-8DC5-4DE99CBFE9CAQ50585724-DC789C49-6460-4297-A758-589C79A58B3DQ51115531-B3E8233C-2E52-41A3-9E17-A9BC94F0E765
P2860
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The impact of HER2 phenotype o ...... pective study in 107 patients.
@ast
The impact of HER2 phenotype o ...... pective study in 107 patients.
@en
type
label
The impact of HER2 phenotype o ...... pective study in 107 patients.
@ast
The impact of HER2 phenotype o ...... pective study in 107 patients.
@en
prefLabel
The impact of HER2 phenotype o ...... pective study in 107 patients.
@ast
The impact of HER2 phenotype o ...... pective study in 107 patients.
@en
P2093
P2860
P50
P1433
P1476
The impact of HER2 phenotype o ...... pective study in 107 patients.
@en
P2093
Andreas Daniel Hartkopf
Birgitt Schönfisch
Christof Sohn
Juliane Nees
Klaus Pantel
Markus Wallwiener
P2860
P2888
P356
10.1186/S12885-015-1423-6
P407
P50
P577
2015-05-14T00:00:00Z
P6179
1042980424